enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Ozempic’s health benefits keep growing, but are the risks ...

   www.aol.com/ozempic-health-benefits-keep-growing...

   A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

3. Largest-ever Ozempic and GLP-1 drug study finds they ... - AOL

   www.aol.com/finance/largest-ever-ozempic-glp-1...

   About 215,000 used GLP-1 drugs, while the rest were taking various other diabetes medications. ... A new frontier of possible uses for these drugs likely depends in part on the answer.

4. Diabetes medication - Wikipedia

   en.wikipedia.org/wiki/Diabetes_medication

   Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.

5. A diabetes drug may help prevent dementia, new research shows

   www.aol.com/diabetes-drug-may-help-prevent...

   SGLT-2 inhibitors are relatively new drugs that treat type 2 diabetes. The first SGLT-2 inhibitor approved for use in the United States was dapagliflozin (Farxiga), in 2014.

6. NNC2215 - Wikipedia

   en.wikipedia.org/wiki/NNC2215

   A glucose sensitive treatment method for diabetes have long been pursued by science since 1979. [4] Such protein is expected to solve the problem of fluctuations of blood sugar levels. For diabetes patients, skipping meal alone could lead to hypoglycemia, which is a common complication could cause loss of consciousness or seizures. [5]

7. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were initially developed for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.